This trial led to a multicenter, randomized, double-blind, placebo-controlled phase 3 study (ClarIDHy), which included 185 adult patients with advanced CCA with IDH1 mutations who had progressed on previous therapy [34]. Here, IDH1 is linked to cholangiocarcinoma.